Literature DB >> 9696816

Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro.

C Bourgeois1, J B Bour, K Lidholt, C Gauthray, P Pothier.   

Abstract

Addition of heparin to the virus culture inhibited syncytial plaque formation due to respiratory syncytial virus (RSV). Moreover, pretreatment of the virus with heparinase or an inhibitor of heparin, protamine, greatly reduced virus infectivity. Two anti-heparan sulfate antibodies stained RSV-infected cells, but not noninfected cells, by immunofluorescence. One of the antibodies was capable of neutralizing RSV infection in vitro. These results prove that heparin-like structures identified on RSV play a major role in early stages of infection. The RSV G protein is the attachment protein. Both anti-heparan sulfate antibodies specifically bound to this protein. Enzymatic digestion of polysaccharides in the G protein reduced the binding, which indicates that heparin-like structures are on the G protein. Such oligosaccharides may therefore participate in the attachment of the virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696816      PMCID: PMC109944     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus.

Authors:  C Bourgeois; C Corvaisier; J B Bour; E Kohli; P Pothier
Journal:  J Gen Virol       Date:  1991-05       Impact factor: 3.891

2.  Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus.

Authors:  P L Collins; G Mottet
Journal:  J Gen Virol       Date:  1991-12       Impact factor: 3.891

3.  Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.

Authors:  M Hosoya; J Balzarini; S Shigeta; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses.

Authors:  M K Spriggs; R A Olmsted; S Venkatesan; J E Coligan; P L Collins
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

5.  Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium.

Authors:  A Martin-Gallardo; E Fleischer; S A Doyle; R Arumugham; P L Collins; S W Hildreth; P R Paradiso
Journal:  J Gen Virol       Date:  1993-03       Impact factor: 3.891

6.  Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation.

Authors:  G W Wertz; M Krieger; L A Ball
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

7.  Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A.

Authors:  P L Collins; G Mottet
Journal:  J Gen Virol       Date:  1992-04       Impact factor: 3.891

8.  The G protein of human respiratory syncytial virus: significance of carbohydrate side-chains and the C-terminal end to its antigenicity.

Authors:  C Palomo; B García-Barreno; C Peñas; J A Melero
Journal:  J Gen Virol       Date:  1991-03       Impact factor: 3.891

9.  Heparinase II from Flavobacterium heparinum. HPLC analysis of the saccharides generated from chemically modified heparins.

Authors:  C F Moffat; M W McLean; W F Long; F B Williamson
Journal:  Eur J Biochem       Date:  1991-12-05

10.  Polylactosaminoglycan modification of the respiratory syncytial virus small hydrophobic (SH) protein: a conserved feature among human and bovine respiratory syncytial viruses.

Authors:  K Anderson; A M King; R A Lerch; G W Wertz
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

View more
  32 in total

1.  The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.

Authors:  Michael N Teng; Peter L Collins
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice.

Authors:  Karen A Herd; Suresh Mahalingam; Ian M Mackay; Michael Nissen; Theo P Sloots; Robert W Tindle
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene.

Authors:  S Techaarpornkul; N Barretto; M E Peeples
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Heparan Sulfate Proteoglycan Is an Important Attachment Factor for Cell Entry of Akabane and Schmallenberg Viruses.

Authors:  Shin Murakami; Akiko Takenaka-Uema; Tomoya Kobayashi; Kentaro Kato; Masayuki Shimojima; Massimo Palmarini; Taisuke Horimoto
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

5.  Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.

Authors:  Roberta L Crim; Susette A Audet; Steven A Feldman; Howard S Mostowski; Judy A Beeler
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

6.  Echoviruses bind heparan sulfate at the cell surface.

Authors:  I G Goodfellow; A B Sioofy; R M Powell; D J Evans
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Authors:  Philip J Budge; Yeqiang Li; Judy A Beeler; Barney S Graham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; Christopher L Parks; Todd S Laughlin; C Kanta Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.

Authors:  Philip J Budge; Jacob Lebowitz; Barney S Graham
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

10.  Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein.

Authors:  Janet L Douglas; Marites L Panis; Edmund Ho; Kuei-Ying Lin; Steve H Krawczyk; Deborah M Grant; Ruby Cai; Swami Swaminathan; Tomas Cihlar
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.